C
Christopher B. McLeland
Researcher at Science Applications International Corporation
Publications - 4
Citations - 1847
Christopher B. McLeland is an academic researcher from Science Applications International Corporation. The author has contributed to research in topics: Autophagy & Autophagosome. The author has an hindex of 4, co-authored 4 publications receiving 1710 citations.
Papers
More filters
Journal ArticleDOI
Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy.
Parag Aggarwal,Jennifer B. Hall,Christopher B. McLeland,Marina A. Dobrovolskaia,Scott E. McNeil +4 more
TL;DR: Recent research on nanoparticle physicochemical properties important for protein binding, techniques for isolation and identification of nanoparticle-bound proteins, and how these proteins can influence particle biodistribution and biocompatibility are reviewed.
Journal ArticleDOI
Induction of Autophagy in Porcine Kidney Cells by Quantum Dots: A Common Cellular Response to Nanomaterials?
Stephan T. Stern,Banu Zolnik,Christopher B. McLeland,Jeffery Clogston,Jiwen Zheng,Scott E. McNeil +5 more
TL;DR: Evidence of extensive autophagy in QD-treated cells, as determined by Lysotracker Red dye uptake, TEM, and LC3 immunobloting, suggests that QD cytotoxicity is dependent upon properties of the particle as a whole, and not exclusively the metal core materials.
Journal ArticleDOI
Synergistic combination therapy with nanoliposomal C6-ceramide and vinblastine is associated with autophagy dysfunction in hepatocarcinoma and colorectal cancer models.
Pavan P. Adiseshaiah,Jeffrey D. Clogston,Christopher B. McLeland,Jamie Rodriguez,Timothy M. Potter,Barry W. Neun,Sarah L. Skoczen,Sriram S. Shanmugavelandy,Mark Kester,Stephan T. Stern,Scott E. McNeil +10 more
TL;DR: In vitro and in vivo data support a synergistic antitumor activity of the nanoliposomal C6-ceramide and vinblastine combination, potentially mediated by an autophagy mechanism.
Book ChapterDOI
Autophagy monitoring assay: qualitative analysis of MAP LC3-I to II conversion by immunoblot.
TL;DR: This work presents a method to monitor autophagy by measurement the autophagosome marker LC3-II, a phosphatidylethanolamine-conjugated form of microtubule-associated protein 1 light chain 3-I (MAPLC3-I), and suggests treatment-related changes in expression should be further evaluated by morphological assessment.